CN Patent

CN120152976A — 抗冠状病毒化合物及其组合物和用途

Assigned to Shanghai Kejun Pharmaceutical Technology Co ltd · Expires 2025-06-13 · 1y expired

What this patent protects

本公开涉及在抑制RNA聚合酶中表现出活性的化合物，以及包含这些化合物的药物组合物和通过施用这些化合物或药物组合物来治疗病毒感染的方法。

USPTO Abstract

本公开涉及在抑制RNA聚合酶中表现出活性的化合物，以及包含这些化合物的药物组合物和通过施用这些化合物或药物组合物来治疗病毒感染的方法。

Drugs covered by this patent

Veklury (remdesivir) · Gilead Sciences

Patent Metadata

Patent number: CN120152976A
Jurisdiction: CN
Classification: —
Expires: 2025-06-13
Drug substance claim: No
Drug product claim: No
Assignee: Shanghai Kejun Pharmaceutical Technology Co ltd
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.